Bajaj HealthCare Limited

BAJAJHCARE

INE411U01027

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-06-14 EDT			5-day change	1st Jan Change
314.8 ^INR	+1.45%		+6.77%	-16.23%

05-24	Bajaj HealthCare Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-24	Bajaj HealthCare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Bajaj Healthcare Limited Recommends Final Dividend for the Financial Year Ended 31St March, 2024

May 24, 2024 at 12:11 pm

Bajaj HealthCare Limited recommended a final dividend of 20% i.e. INR 1.00/- per equity share on face value of INR 5/- each for the financial year ended 31st March, 2024, subject to approval of shareholders in the ensuing Annual General Meeting.

Latest news about Bajaj HealthCare Limited

Bajaj HealthCare Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-24	CI
Bajaj HealthCare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-24	CI
Bajaj Healthcare Limited Recommends Final Dividend for the Financial Year Ended 31St March, 2024	05-24	CI
Bajaj Healthcare Appoints CFO	05-06	MT
Bajaj Healthcare Limited Appoints Dayashankar Patel as the Chief Financial Officer	05-06	CI
Bajaj Healthcare Bags Contract Manufacturing for APIs from UK, EU Customers; Shares Jump 14%	02-28	MT
Bajaj Healthcare Limited Enters Definitive CDMO Agreement for 15 APIs with UK/EU Customers	02-28	CI
Indian Equities Rebound, Helped by Gains in IT, Auto and Metal Stocks	02-22	MT
Bajaj Healthcare CFO Steps Down	02-11	MT
Bajaj Healthcare Limited Announces Executive Changes	02-09	CI
Bajaj Healthcare Limited Announces Resignation of Rupesh Nikam as Chief Financial Officer	02-09	CI
Bajaj HealthCare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-09	CI
Bajaj Healthcare Limited Announces Resignation of Aakashkumar Keshari from the Post of Company Secretary & Compliance Officer Effective	02-03	CI
Bajaj Healthcare Limited Announces Resignation of Avinash K. Dalal as Non-Executive Independent Director	12-26	CI
Bajaj Healthcare Appoints Chief Technical Officer	11-09	MT
Bajaj Healthcare Limited Approves Appointment of Amit Rajan as Chief Technical Officer	11-09	CI
Bajaj HealthCare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Bajaj Healthcare Commissions Alkaloid Extraction Plant	23-10-18	MT
Bajaj Healthcare Completes Constrution of Alkaloid Extraction Plant in Gujarat, India	23-10-16	MT
Bajaj Healthcare Limited Announces Successfully Completion of Construction of Alkaloid Extraction Plant at Vadodara, Gujarat Unit	23-10-13	CI
Bajaj Healthcare Gets Vadodara, India Unit Inspection Report from US FDA	23-09-13	MT
Bajaj Healthcare Swings to Loss in Fiscal Q1	23-08-16	MT
Bajaj HealthCare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Bajaj HealthCare Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Bajaj HealthCare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-30	CI

Chart Bajaj HealthCare Limited

Duration

Period

More charts

Company Profile

Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. Its segments include Bulk Drugs and Formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. Its APIs include ascorbic acid, CH Base and its derivatives, citicoline sodium, carbamazepine, theobromine, ferrous ascorbate, doxofylline, oxcarbazepine, choline bitartrate and its derivatives, octenidine dihydrochloride, vildagliptin, ticagrelor, diosmin, hesperidin and others. Its FDFs include Cellin 500, Septran DS Tablet, Vitajaj C tables 500mg, Ticajaj 90 tablets, Ecojaj 75mg & 150mg, Deferajaj 400mg & 500mg, Vildajaj 50mg and Vildajaj M 50/500. It also offers Inositol Nicotinate and Magnesium L-Threonate.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAJAJ HEALTHCARE LIMITED	-16.23%	104M
ELI LILLY AND COMPANY	+51.64%	791B
NOVO NORDISK A/S	+40.45%	630B
MERCK & CO., INC.	+17.31%	328B
ABBVIE INC.	+9.11%	298B
ASTRAZENECA PLC	+17.25%	246B
ROCHE HOLDING AG	+0.41%	225B
NOVARTIS AG	+10.22%	218B
AMGEN INC.	+4.43%	160B
PFIZER, INC.	-5.92%	156B